ClinicalTrials.gg
RecruitingNCT07383844Feels-MiciUpdated Feb 3, 2026

Analysis of Barriers and Facilitators to Adapted Physical Activity for Pediatric Patients With Chronic Inflammatory Bowel Diseases

An observational study in Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), sponsored by Fondation Lenval. Recruiting at 1 site in France. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Fondation Lenval · Observational

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
60
Ages
10 Years to 17 Years
Sex
All
01

Study summary

This study aims to identify perceived barriers and facilitators to regular physical activity among children and adolescents with inflammatory bowel disease (IBD) followed in pediatric gastroenterology. Approximately 60 participants aged 10-17 years will complete two self-administered questionnaires (CAPAS-Q for physical activity/sedentary behavior and IMPACT-III for health-related quality of life) and take part in a single semi-structured interview exploring experiences, obstacles, and levers to support sustainable physical activity. Relevant clinical data (disease characteristics, treatment and selected routine clinical parameters) will be extracted from the medical record. Participation is limited to one visit (about 45-60 minutes) during a routine hospital appointment, with no additional intervention or follow-up required.

02

Conditions studied

  • Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)

Keywords

  • physical activity
03

In context

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 426 are open to participants now.

This study's planned enrollment of 60 is below the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.

Browse Inflammatory Bowel Diseases studies →

Lead sponsor

Fondation Lenval is the lead sponsor of 61 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Aged 10 to 17 years at inclusion.

  • Diagnosed inflammatory bowel disease (Crohn's disease or ulcerative colitis) confirmed and diagnosed for at least 6 months.
  • Followed in the pediatric gastroenterology department at Hôpital Lenval (CHU de Nice).
  • Sufficient cognitive and language abilities to understand questionnaires and participate in an individual interview.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 10 to 17 years at inclusion.
  • Diagnosed inflammatory bowel disease (Crohn's disease or ulcerative colitis) confirmed and diagnosed for at least 6 months.
  • Followed in the pediatric gastroenterology department at Hôpital Lenval (CHU de Nice).
  • Sufficient cognitive and language abilities to understand questionnaires and participate in an individual interview.
  • Affiliated to, or beneficiary of, a social security scheme.
  • no parental objection to participation (non-opposition).

Exclusion criteria

Exclusion Criteria:

  • Younger than 10 years or older than 17 years.
  • No IBD diagnosis, or IBD diagnosed less than 6 months ago.
  • Associated chronic condition (neurological, metabolic, psychiatric, or other) likely to interfere with questionnaire completion or interview participation.
  • Major language or cognitive impairment preventing adequate understanding or interview participation.
  • Not affiliated to, or not beneficiary of, a social security scheme.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pediatric IBD participants (questionnaires + interview)

    This study does not involve any therapeutic or behavioral intervention. The "intervention" corresponds to data collection during a single visit: participants complete two self-administered questionnaires (CAPAS-Q and IMPACT-III) and participate in a semi-structured interview about perceived barriers and facilitators to physical activity. No counseling, training, or treatment is provided.

    Other: IMPACT-III questionnaires · Other: Data collection: CAPAS-Q · Other: semi-structured interview

Interventions

  • OtherIMPACT-III questionnaires

    Participants complete the self-administered questionnaires IMPACT-III)

  • OtherData collection: CAPAS-Q

    Participants complete the self-administered questionnaires CAPAS-Q.

  • Othersemi-structured interview

    participate in a semi-structured interview about perceived barriers and facilitators to physical activity. No counseling, training, or treatment is provided.

06

What researchers measure

Primary outcomes

  1. Perceived barriers and facilitators to regular physical activity

    Assessed through a single semi-structured interview. Qualitative thematic analysis will be used to identify and categorize perceived barriers and facilitators to regular physical activity in pediatric IBD.

    Time frame: at the inclusion

Secondary outcomes

  1. Physical activity level and sedentary behavior (CAPAS-Q)

    Measured using the CAPAS-Q self-administered questionnaire to describe participants' physical activity and sedentary behavior.

    Time frame: at the inclusion

  2. Health-related quality of life (IMPACT-III)

    Measured using the IMPACT-III self-administered questionnaire to assess health-related quality of life in pediatric IBD.

    Time frame: at the inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07383844
Lead sponsor
Fondation Lenval
Responsible party
Sponsor
First posted
Feb 3, 2026
Start date
Jan 21, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Feb 3, 2026

Study contacts

ALINE JOULIE
Contact
joulie.a@chu-nice.fr
0492030520 ext. +33
Olivier Courbette
Contact
olivier.courbette@hpu.lenval.com
+33.4.92.03.05.65 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion